GlycoBind antibody reagents

Pipeline

Pipeline



GNX102

Glycan-directed Anti-cancer Antibody

GNX102 was developed with the goal of tackling one of the most common and deadliest cancers, GI cancer. GNX102 is a humanized antibody targeting a cancer-specific glycan prevalent on several types of cancer cells (gastric, colon, and pancreatic cancer). By employing a novel binding mechanism, this drug has shown promising safety and efficacy results at low dosages (0.04 mg/kg) in a series of preclinical animal models. GlycoNex is looking for licensing and co-development partners as we move on to IND and US FDA submission in 2019.

 

Indication

  • GI cancer

Efficacy

US IND Submission in Q2 2019

 

FIH Study in Q1 2020

Bispecific Antibody

Armed T-cell Therapy

In order to eliminate the concerns of current T-cell immunotherapy, such as the risk of genotoxicity causing oncogenesis of T-cells through the virus-based gene transduction and low efficiency of establishing genetically engineered T-cells (> 30 days), Dr. Kuo-Hsiang Chuang‘s Lab at Taipei Medical University has developed a novel platform technology to generate armed T-cells. By co-culturing the anti-glycan / anti-CD3 BsAb and peripheral blood mononuclear cells (PBMC) for 10 days, the glycan specific-armed T-cells will be developed through this one step modification, and there is no need to conduct the gene modification during this process.

GlycoNex is developing the innovative bi-specific antibody and collaborating with Dr. Chuang to generate armed T-cells targeting glycan antigens on cancer cells.

 

​ ​